Residence Hall Program and Perception of University Environment

I have always maintained that at-risk students were often blamed for their lack of success, rather than supported to overcome their prior educational challenges. As a second year residence hall director I had the privilege of working in a building with two distant wings. With the support of my mentor, Dr. Eugene J. Cech, Director of Testing, we developed a residence life program designed to assist summer lower-quarter high school graduates to be successful in college. The quality of residence life does make a difference. The journal, College Student Survey, no longer appears to be published

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Residence Hall Program and Perception of University Environment

I have always maintained that at-risk students were often blamed for their lack of success, rather than supported to overcome their prior educational challenges. As a second year residence hall director I had the privilege of working in a building with two distant wings. With the support of my mentor, Dr. Eugene J. Cech, Director of Testing, we developed a residence life program designed to assist summer lower-quarter high school graduates to be successful in college. The quality of residence life does make a difference. The journal, College Student Survey, no longer appears to be published

Design and Testing of a Closed, Stirring Respirometer for Measuring Oxygen Consumption of Channel Catfish Eggs

A closed, stirring respirometer was designed to agitate small egg mass samples of channel catfish Ictalurus punctatus while measuring oxygen consumption by the eggs. Egg mass samples ranging in size from 15 to 46 g were placed on a screen platform above a magnetic stir bar in the respirometer; the degree of agitation was controlled with a magnetic stir plate. Dissolved oxygen (DO) concentration and temperature were measured with a luminescent DO sensor and meter. The respirometer was used to determine routine metabolic rate and limiting oxygen concentration (the presumed hypometabolic transition zone) on egg mass samples from 10 different spawns at 0 to 5 d postfertilization. Routine metabolic rate increased from 4.8 ± 1.3 (0 d postfertilization) to 174.0 ± 7.8 mg O2 ·kg-1 ·h-1 (5 d postfertilization). The limiting oxygen concentration increased similarly up to 87.0% ± 2.7% (maximum individual value = 95.9%) air saturation by 5 d postfertilization. The respirometer described could not be used for sac fry, but it proved effective with clumped channel catfish eggs. Preliminary channel catfish hatchery management recommendations are to maintain DO concentrations in hatchery troughs at air saturation at least during the last day of egg development

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)